SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 19, 2003

CRYOLIFE, INC.
(Exact name of registrant as specified in its charter)

Florida
(State or other jurisdiction of incorporation)

1-13165	59-2417093
(Commission File Number)	(IRS Employer Identification No.)

1655 Roberts Boulevard N.W., Kennesaw, Georgia 30144
(Address of principal executive offices, including zip code)

(770) 419-3355
(Registrant's telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE.

On August 19, 2003 and August 20, 2003, respectively, CryoLife, Inc. ("CryoLife") issued press releases relating to the appointment of Thomas J. Lynch, J.D., Ph.D., as Vice President of Regulatory Affairs & Quality Assurance, and Gregory Ray, M.D., as Associate Medical Director. CryoLife hereby incorporates by reference herein the information set forth in its Press Releases dated August 19, 2003 and August 20, 2003, respectively, copies of which are attached hereto as Exhibits 99.1 and 99.2.

ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.

(a) Financial Statements.

Not applicable.

(b) Pro Forma Financial Information.

Not applicable.

(c) Exhibits.

Exhibit Number Description

99.1	Press Release dated August 19, 2003
99.2	Press Release dated August 20, 2003

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, CryoLife has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CRYOLIFE, INC.

Date: August 21, 2003

By: /s/ D. Ashley Lee

Name: D. Ashley Lee
Title: Vice President, Chief Financial Officer and Treasurer

EXHIBIT INDEX

EXHIBIT 99.1

[COMPANY LOGO]

CRYOLIFE(R) NAMES THOMAS J. LYNCH, J.D., PH.D., VICE PRESIDENT, REGULATORY AFFAIRS AND QUALITY ASSURANCE

ATLANTA, Aug. 19 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), announced today that Thomas J. Lynch, J.D., Ph.D., has been appointed Vice President, Regulatory Affairs and Quality Assurance. He will report to Steven G. Anderson, President and CEO. Dr. Lynch will oversee the Company's Regulatory Affairs and Quality Assurance operations and will be responsible for compliance with legislative and regulatory requirements.

Dr. Lynch joins CryoLife from Clearant, Inc., a leader in pathogen inactivation (sterilization) for biological products, where for the past three years he was the Senior Vice President, Regulatory Affairs and Quality Assurance, responsible for developing and implementing improved safety processes and procedures for new and existing biopharmaceutical products. Before joining Clearant, Dr. Lynch served as deputy director for the U.S. Food and Drug Administration (FDA) Division of Hematology, Office of Blood Research and Review, Center for Biologies Evaluation and Research. He worked at this division of the FDA for six years, where he was involved in new product review and approvals, and in regulatory compliance. Prior to that, he worked as a research scientist in several positions in academia, at the National Institutes of Health (NIH), and the Biotech industry.

"Tom's extensive experience and knowledge will be a great benefit to CryoLife and I am confident that he will contribute to our future successes," Anderson said. "He will play a key role in our organization and his leadership will be instrumental in helping to move the Company's regulatory and quality assurance initiatives forward."

Dr. Lynch holds a doctorate in biochemistry from Wayne State University, and a Law degree from Georgetown University.

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiovascular and vascular surgeries throughout the United States and Canada. The Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels and is CE marked in the European Community and approved in Canada for use in soft tissue repair and approved in Australia for use in vascular and pulmonary sealing and repair. The Company also manufactures the SynerGraft(R) Vascular Graft, which is CE marked for distribution within the European Community.

For additional information about the company, visit CryoLife's web site: http://www.cryolife.com .

Contact: Joseph T. Schepers
Vice President, Corporate Communications
(770) 419-3355

Rosa Herrera
Fleishman Hillard
(404) 739-0153

EXHIBIT 99.2

[COMPANY LOGO]

CRYOLIFE(R) NAMES GREGORY RAY, MD ASSOCIATE MEDICAL DIRECTOR

ATLANTA, Aug. 20 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), announced today that Gregory Ray, M.D., a board certified pathologist, has been appointed Associate Medical Director. Dr. Ray will report directly to J. Robin de Andrade, M.D., Medical Director. Dr. Ray will be responsible for establishing Cryolife's in-house pathology laboratory, which will work closely with the Quality Assurance department. Dr. Ray will also provide expertise in determining suitability of donors and tissues and will interact with tissue procurement organizations and medical examiners.

Dr. Ray joins CryoLife from Pathworks Anatomic Laboratory where he has worked since 2000 and served most recently as medical director. Dr. Ray also worked for the Georgia Bureau of Investigation, Division of Forensic Sciences, Emory University School of Medicine and North Lake Medical Center.

"Gregory is highly and uniquely qualified to establish our pathology lab as well as coordinate activities with procurement organizations and medical examiners," said J. Robin de Andrade, M.D., CryoLife's Medical Director. "His experience will help us work toward increasing the efficiency and timeliness of the Company's tissue processing."

Dr. Ray received a B.S. from Oglethorpe University, and an M.D. from the Medical College of Georgia and completed residence training in pathology and laboratory medicine at Emory University.

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiovascular and vascular surgeries throughout the United States and Canada. The Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels and is CE marked in the European Community and approved in Canada for use in soft tissue repair and approved in Australia for use in vascular and pulmonary sealing and repair. The Company also manufactures the SynerGraft(R) Vascular Graft, which is CE marked for distribution within the European Community.

For additional information about the company, visit CryoLife's web site: http://www.cryolife.com.

Joseph T. Schepers
Vice President, Corporate Communications
770) 419-3355

Rosa Herrera
Fleishman Hillard
(404) 739-0153